Patient P-02066
Synthetic patientMETA-24 · Day 168 · 45–54 · M · baseline S07Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
2%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S07
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- GI instability-5
- Inflammatory activity-5
- Toxicity+5
- Nutritional resilience+4
- Treatment adherence+4
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable96 min
stable · +2.9 vs previous 14 d
Sleep duration
Wearable7.8 h
improving · +0.3 vs previous 14 d
Energy level
Daily log8.2/10
improving · +0.6 vs previous 14 d
Steps
Wearable10,156
stable · +337 vs previous 14 d
GI burden
Companion0/100
improving · -4.6 vs previous 14 d
Adherence
Companion95.2 %
stable · +1.4 vs previous 14 d
Sleep quality
Wearable70.6/100
improving · +4.6 vs previous 14 d
Glucose, CGM daily mean
CGM118 mg/dL
stable · -1.1 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 102 from the failing basin, 19 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -4.5 next day on high-intake days · n 26
Would not help
- Keep caffeine lowGI +5 next day on high-intake days · n 17
- Keep alcohol lowGI +3.7 next day on high-intake days · n 20
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Caffeine+5detractor · 95%
- Protein-4.5supporter · 95%
- Alcohol+3.7detractor · 95%
- Dietary fat load+1.2no signal · 26%
- Simple carbohydrates-1no signal · 18%
- Insoluble fibre-0.9no signal · 22%
- Ultra-processed food-0.4no signal · 15%
- Histamine load-0.3no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 3.8 · butyrate capacity 46/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 46 ms
- Sleep
- 8.2 h
- Steps
- 10,575
- Resting HR
- 54 bpm
Daily log: GI score 0, nutritional resilience 76, adherence 95.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02555 | 51% | S01 | AD-05 | no change | 79 |
| P-02277 | 42% | S05 | AD-05 | improved | 92 |
| P-02282 | 43% | S01 | BR-03 | no change | 88 |
| P-02013 | 37% | S14 | BR-03 | no change | 94 |
| P-02280 | 28% | S07 | BR-03 | no change | 50 |
| P-02193 | 37% | S11 | CR-01 | improved | 87 |
| P-02081 | 43% | S20 | DT-01 | no change | 88 |
| P-02249 | 40% | S09 | DT-01 | improved | 100 |
| P-02565 | 38% | S09 | DT-01 | no change | 79 |
| P-02337 | 34% | S18 | DT-01 | no change | 100 |
| P-02462 | 29% | S12 | DT-01 | improved | 65 |
| P-02518 | 29% | S17 | DT-01 | improved | 68 |